C:\Program Files\Stnexp\Queries\10038306.str (from earlier parent) $\mathrm{o}^{-\theta}_{-C}^{-1}$ 210-22 chain nodes : 18 19 20 21 22 26 ring nodes :

1 2 3 4 5 6 7 8 12 13 14 15 16 17

chain bonds :

7-26 13-26 16-18 18-19 18-20 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16

16-17

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 7-26 8-9 12-13 12-17 13-14 13-26 14-15 15-16 16-17 16-18 18-19 18-20 21-22

isolated ring systems : containing 1 : 12 :

G1:C, N

G2:Cy,[*1]

Connectivity :

26:2 M minimum RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS

26:CLASS

=> s 16

SAMPLE SEARCH INITIATED 19:44:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 178 TO ITERATE

100.0% PROCESSED 178 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

2760 TO 4360

PROJECTED ANSWERS:

0 TO

L7

0 SEA SSS SAM L6

=> s 16 sss full

FULL SEARCH INITIATED 19:44:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3272 TO ITERATE

100.0% PROCESSED 3272 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L8

2 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
155.84
331.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE

0.00 -1.39

FILE 'CAPLUS' ENTERED AT 19:44:37 ON 17 APR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2004 VOL 140 ISS 17 FILE LAST UPDATED: 16 Apr 2004 (20040416/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 18

L9 2 L8

=> d l9 1-2 bib abs hitstr

```
ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
     2002:832569 CAPLUS
DN
     137:337880
TΙ
     Preparation of indole, azaindole, and related heterocyclic
     piperazinecarboxamides for treatment of AIDS
     Wang, Tao; Wallace, Owen B.; Meanwell, Nicholas A.; Zhang, Zhongxing;
IN
     Bender, John A.; Kadow, John F.; Yeung, Kap-Sun
PA
     Bristol-Myers Squibb Company, USA
     PCT Int. Appl., 111 pp.
SO
     CODEN: PIXXD2
                                                         5 aw
DT
     Patent
     English
LA
FAN.CNT 1
     PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO.
                                                             DATE
                                           ______
PΙ
     WO 2002085301
                      A2
                                           WO 2002-US12856 20020423
                            20021031
     WO 2002085301
                      Α3
                            20030227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
                                           US 2002-127256 20020422
EP 2002-764315 20020423
     US 2003096825
                       Α1
                            20030522
                                                                       5aw
     EP 1381366
                            20040121
                       A2
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2001-286347P
                     P
                            20010425
     WO 2002-US12856
                       W
                            20020423
     MARPAT 137:337880
OS
GΙ
```

This invention provides indole, azaindole, and related heterocyclic piperazinecarboxamides Q(C(O))m(CR8R8')n(C(O))pTC(O)A (1; variables defined below; e.g. N-(benzoyl)-N'-[2-(indol-2-yl)-2-oxo-1-cyanoethyl]piperazine (shown as I)) having drug and bio-affecting properties, their pharmaceutical compns. and method of use. These compds. possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry

inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. EC50 ranges against HIV-1 are given for about 30 of the claimed compds.; for example, N-(benzoyl)-N'-[2-(6-methoxyindol-2-yl)-2-oxo-1-cyanoethyl]-3-methylpiperazine has an EC50 <1 μ M. Although the methods of preparation are not claimed, 32 example prepns. of 1 and 6 example prepns. of intermediates are included. In 1: Q is shown as II (dotted line may be a bond); A is C1-6alkoxy, C1-6alkyl, C3-7cycloalkyl, Ph, and heteroaryl; T is piperazine-1,4-diyl; U is NR7, O, or S; V is C(H)kR1, O or N(R7)k; W is CR3 or NR10; X is CR4 or NR10; Y is CR5 or NR10; Z is CR6 or NR10; k is 0 or 1; m, n, and p are 0-2 provided that the sum of m, n, and p must equal 1 or 2; R8 and R8 are H, hydroxy, C1-6alkyl, C1-6alkoxy, cyano, and fluoro, or R8 and R8' taken together form :0, :S, :NOR9, or :NH; other variables and provisos are given in the claims.

IT 474011-86-4P, 1-(Benzoyl)-4-[(4-fluoroindolin-3yl)acetyl]piperazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); PIOL (Piological attack); PREP (Propagation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indole, azaindole, and related heterocyclic piperazinecarboxamides for treatment of AIDS)

RN 474011-86-4 CAPLUS CN Piperazine, 1-benzo

Piperazine, 1-benzoyl-4-[(4-fluoro-2,3-dihydro-1H-indol-3-yl)acetyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & O \\ \hline & N & O \\ \hline & C \\ & C \\ & & C \\ \end{array}$$

```
L9
     ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     2002:51452 CAPLUS
DN
      136:118470
TI
     Preparation of substituted indoleoxoacetylpiperazines with antiviral
      activity against HIV-1
     Wallace, Owen B.; Wang, Tao; Yeung, Kap-Sun; Pearce, Bradley C.; Meanwell,
IN
     Nicholas A.; Qiu, Zhilei; Fang, Haiquan; Xue, Qiufen May; Yin, Zhiwei
     Bristol-Myers Squibb Company, USA
PA
     PCT Int. Appl., 277 pp.
SO
     CODEN: PIXXD2
DT
      Patent
     English
LA
FAN.CNT 2
      PATENT NO.
                          KIND
                                 DATE
                                                   APPLICATION NO.
                                                                       DATE
      ______
                                 -----
PΙ
     WO 2002004440
                           A1
                                 20020117
                                                   WO 2001-US20300
                                                                       20010626
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
               LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
               RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
               DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1299382
                           A1
                                 20030409
                                                  EP 2001-946715
                                                                       20010626
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
      JP 2004502768
                           T2
                                 20040129
                                                   JP 2002-509305
                                                                       20010626
PRAI US 2000-217444P
                           Ρ
                                 20000710
     US 2001-265978P
                           Ρ
                                 20010202
     WO 2001-US20300
                                 20010626
OS
     MARPAT 136:118470
GΙ
```

Ι

AB Indoleoxoacetylpiperazines I [A = (un) substituted alkoxy, aryl, heteroaryl; W = (un) substituted piperazino; R1 = H; R2-R5 = H, halogen, CN, NO2, (un) substituted NH2, OH, (un) substituted alkyl, cycloalkyl, alkoxy, CO2H, acyl, carbamoyl, amidino, aryl, heteroaryl, heterocyclic; R6 = H, alkyl] and their 2,3-dihydroindole analogs were prepared for use as virucides in the treatment of HIV and AIDS. Thus, 2-bromo-5fluoronitrobenzene was cyclized with CH2:CHMqBr to give 4-fluoro-7-bromoindole, which was treated with ClCOCO2Et, followed by ester hydrolysis to give 4-fluoro-7-bromo-3-indoleglyoxylic acid. This acid was amidated with N-benzoylpiperazine and treated with PhSnBu3 to give I [A = R5 = Ph, W = piperazino, R1, R3, R4, R6 = H, R2 = F]. This compound gave >98% inhibition of HIV-1 infection in HeLa cells. IT 389630-94-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted indoleoxoacetylpiperazines with antiviral activity against HIV-1)

RN 389630-94-8 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-[[(2R)-4-benzoyl-2-methyl-1-piperazinyl]oxoacetyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION 344.62 ENTRY FULL ESTIMATED COST 13.02 344.62 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -1.39 -2.78

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:49:18 ON 17 APR 2004